Sign In

Login

Password

Forgot Password ? Sign Up

Alirocumab (Vietnamese Wikipedia)

Analysis of information sources in references of the Wikipedia article "Alirocumab" in Vietnamese language version.

refsWebsite
Global rank Vietnamese rank
8doi.org
2nd place
2nd place
8nih.gov
4th place
7th place
3web.archive.org
1st place
1st place
2nytimes.com
7th place
23rd place
2fda.gov
447th place
625th place
1who.int
195th place
120th place
1msn.com
117th place
172nd place
1uendocrine.com
low place
low place
1nature.com
234th place
153rd place
1biotechdaily.com
low place
low place
1nascentbiotech.com
low place
low place
1shareholder.com
6,233rd place
2,905th place
1forbes.com
54th place
57th place
1medscape.com
719th place
1,344th place
1wsj.com
79th place
171st place
1bloomberg.com
99th place
156th place
1reuters.com
49th place
78th place
1fiercepharmamarketing.com
low place
low place

biotechdaily.com

bloomberg.com

doi.org

  • Kazi, Dhruv S.; Moran, Andrew E.; Coxson, Pamela G.; Penko, Joanne; Ollendorf, Daniel A.; Pearson, Steven D.; Tice, Jeffrey A.; Guzman, David; Bibbins-Domingo, Kirsten (ngày 16 tháng 8 năm 2016). “Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease”. JAMA. 316 (7): 743–53. doi:10.1001/jama.2016.11004. PMID 27533159.
  • Weinreich, M; Frishman, W (2014). “Antihyperlipidemic therapies targeting PCSK9”. Cardiology in Review. 22 (3): 140–6. doi:10.1097/CRD.0000000000000014. PMID 24407047.
  • Abifadel M, Elbitar S, El Khoury P, Ghaleb Y, Chémaly M, Moussalli ML, Rabès JP, Varret M, Boileau C (tháng 9 năm 2014). “Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs”. Current Atherosclerosis Reports. 16 (9): 439. doi:10.1007/s11883-014-0439-8. PMID 25052769.
  • Desai NR, Sabatine MS (tháng 2 năm 2015). “PCSK9 inhibition in patients with hypercholesterolemia”. Trends in Cardiovascular Medicine. 25 (7): 567–74. doi:10.1016/j.tcm.2015.01.009. PMID 25771732.
  • Sheridan C (tháng 12 năm 2013). “Phase 3 data for PCSK9 inhibitor wows”. Nature Biotechnology. 31 (12): 1057–8. doi:10.1038/nbt1213-1057. PMID 24316621.
  • Stein EA, Mellis S, Yancopoulos GD, Stahl N, Logan D, Smith WB, Lisbon E, Gutierrez M, Webb C, Wu R, Du Y, Kranz T, Gasparino E, Swergold GD (2012). “Effect of a monoclonal antibody to PCSK9 on LDL cholesterol”. N. Engl. J. Med. 366 (12): 1108–18. doi:10.1056/NEJMoa1105803. PMID 22435370.
  • Moriarty PM, Jacobson TA, Bruckert E, Thompson PD, Guyton JR, Baccara-Dinet MT, Gipe D (Nov–Dec 2014). “Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial”. Journal of Clinical Lipidology. 8 (6): 554–61. doi:10.1016/j.jacl.2014.09.007. PMID 25499937.
  • Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ (tháng 4 năm 2015). “Efficacy and safety of alirocumab in reducing lipids and cardiovascular events”. The New England Journal of Medicine. 372 (16): 1489–99. doi:10.1056/NEJMoa1501031. PMID 25773378.

fda.gov

accessdata.fda.gov

fda.gov

fiercepharmamarketing.com

forbes.com

medscape.com

msn.com

nascentbiotech.com

nature.com

nih.gov

pubmed.ncbi.nlm.nih.gov

  • Kazi, Dhruv S.; Moran, Andrew E.; Coxson, Pamela G.; Penko, Joanne; Ollendorf, Daniel A.; Pearson, Steven D.; Tice, Jeffrey A.; Guzman, David; Bibbins-Domingo, Kirsten (ngày 16 tháng 8 năm 2016). “Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease”. JAMA. 316 (7): 743–53. doi:10.1001/jama.2016.11004. PMID 27533159.
  • Weinreich, M; Frishman, W (2014). “Antihyperlipidemic therapies targeting PCSK9”. Cardiology in Review. 22 (3): 140–6. doi:10.1097/CRD.0000000000000014. PMID 24407047.
  • Abifadel M, Elbitar S, El Khoury P, Ghaleb Y, Chémaly M, Moussalli ML, Rabès JP, Varret M, Boileau C (tháng 9 năm 2014). “Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs”. Current Atherosclerosis Reports. 16 (9): 439. doi:10.1007/s11883-014-0439-8. PMID 25052769.
  • Desai NR, Sabatine MS (tháng 2 năm 2015). “PCSK9 inhibition in patients with hypercholesterolemia”. Trends in Cardiovascular Medicine. 25 (7): 567–74. doi:10.1016/j.tcm.2015.01.009. PMID 25771732.
  • Sheridan C (tháng 12 năm 2013). “Phase 3 data for PCSK9 inhibitor wows”. Nature Biotechnology. 31 (12): 1057–8. doi:10.1038/nbt1213-1057. PMID 24316621.
  • Stein EA, Mellis S, Yancopoulos GD, Stahl N, Logan D, Smith WB, Lisbon E, Gutierrez M, Webb C, Wu R, Du Y, Kranz T, Gasparino E, Swergold GD (2012). “Effect of a monoclonal antibody to PCSK9 on LDL cholesterol”. N. Engl. J. Med. 366 (12): 1108–18. doi:10.1056/NEJMoa1105803. PMID 22435370.
  • Moriarty PM, Jacobson TA, Bruckert E, Thompson PD, Guyton JR, Baccara-Dinet MT, Gipe D (Nov–Dec 2014). “Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial”. Journal of Clinical Lipidology. 8 (6): 554–61. doi:10.1016/j.jacl.2014.09.007. PMID 25499937.
  • Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ (tháng 4 năm 2015). “Efficacy and safety of alirocumab in reducing lipids and cardiovascular events”. The New England Journal of Medicine. 372 (16): 1489–99. doi:10.1056/NEJMoa1501031. PMID 25773378.

nytimes.com

reuters.com

shareholder.com

files.shareholder.com

uendocrine.com

web.archive.org

who.int

wsj.com